Jump to content

Senescence-associated secretory phenotype

Edit links
From Wikipedia, the free encyclopedia

Senescence-associated secretory phenotype (SASP) is a phenotype associated with senescent cells wherein those cells secrete high levels of inflammatory cytokines, immune modulators, growth factors, and proteases.[1][2] SASP may also consist of exosomes and ectosomes containing enzymes, microRNA, DNA fragments, chemokines, and other bioactive factors.[3][4] Soluble urokinase plasminogen activator surface receptor is part of SASP, and has been used to identify senescent cells for senolytic therapy.[5] Initially, SASP is immunosuppressive (characterized by TGF-β1 and TGF-β3) and profibrotic, but progresses to become proinflammatory (characterized by IL-1β, IL-6 and IL-8) and fibrolytic.[6][7] SASP is the primary cause of the detrimental effects of senescent cells.[4]

SASP is heterogenous, with the exact composition dependent upon the senescent-cell inducer and the cell type.[4][8] Interleukin 12 (IL-12) and Interleukin 10 (IL-10) are increased more than 200-fold in replicative senescence in contrast to stress-induced senescence or proteosome-inhibited senescence where the increases are about 30-fold or less.[9] Tumor necrosis factor (TNF) is increased 32-fold in stress-induced senescence, 8-fold in replicative senescence, and only slightly in proteosome-inhibited senescence.[9] Interleukin 6 (IL-6) and interleukin 8 (IL-8) are the most conserved and robust features of SASP.[10] But some SASP components are anti-inflammatory.[11]

Senescence and SASP can also occur in post-mitotic cells, notably neurons.[12] The SASP in senescent neurons can vary according to cell type, the initiator of senescence, and the stage of senescence. [12]

An online SASP Atlas serves as a guide to the various types of SASP.[8]

SASP is one of the three main features of senescent cells, the other two features being arrested cell growth, and resistance to apoptosis.[13] SASP factors can include the anti-apoptotic protein Bcl-xL,[14] but growth arrest and SASP production are independently regulated.[15] Although SASP from senescent cells can kill neighboring normal cells, the apoptosis-resistance of senescent cells protects those cells from SASP.[16]

History

[edit]

The concept and abbreviation of SASP was first established by Judith Campisi and her group, who first published on the subject in 2008.[1]

Causes

[edit]

SASP expression is induced by a number of transcription factors, including MLL1 (KMT2A),[17] C/EBPβ, and NF-κB.[18][19] NF-κB and the enzyme CD38 are mutually activating.[20] NF-κB is expressed as a result of inhibition of autophagy-mediated degradation of the transcription factor GATA4.[21][22] GATA4 is activated by the DNA damage response factors, which induce cellular senescence.[21] SASP is both a promoter of DNA damage response and a consequence of DNA damage response, in an autocrine and paracrine manner.[23] Aberrant oncogenes, DNA damage, and oxidative stress induce mitogen-activated protein kinases, which are the upstream regulators of NF-κB.[24][25]

Demethylation of DNA packaging protein Histone H3 (H3K27me3) can lead to up-regulation of genes controlling SASP.[17]

mTOR (mammalian target of rapamycin) is also a key initiator of SASP.[22][26] Interleukin 1 alpha (IL1A) is found on the surface of senescent cells, where it contributes to the production of SASP factors due to a positive feedback loop with NF-κB.[27][28][29] Translation of mRNA for IL1A is highly dependent upon mTOR activity.[30] mTOR activity increases levels of IL1A, mediated by MAPKAPK2.[27] mTOR inhibition of ZFP36L1 prevents this protein from degrading transcripts of numerous components of SASP factors.[31][32] Inhibition of mTOR supports autophagy, which can generate SASP components.[33]

Ribosomal DNA (rDNA) is more vulnerable to DNA damage than DNA elsewhere in the genome such than rDNA instability can lead to cellular senescence, and thus to SASP[34] The high-mobility group proteins (HMGA) can induce senescence and SASP in a p53-dependent manner.[35]

Activation of the retrotransposon LINE1 can result in cytosolic DNA that activates the cGAS–STING cytosolic DNA sensing pathway upregulating SASP by induction of interferon type I.[35] cGAS is essential for induction of cellular senescence by DNA damage.[36]

SASP secretion can also be initiated by the microRNAs miR-146 a/b.[37]

Senescent cells release mt-dsRNA into the cytosol driving the SASP via RIGI/MDA5/MAVS/MFN1. Moreover, senescent cells are hypersensitive to mt-dsRNA-driven inflammation due to reduced levels of PNPT1 and ADAR1.[38]

Pathology

[edit]

Senescent cells are highly metabolically active, producing large amounts of SASP, which is why senescent cells consisting of only 2% or 3% of tissue cells can be a major cause of aging-associated diseases.[32] SASP factors cause non-senescent cells to become senescent.[39][40][41] SASP factors induce insulin resistance.[42] SASP disrupts normal tissue function by producing chronic inflammation, induction of fibrosis and inhibition of stem cells.[43] Transforming growth factor beta family members secreted by senescent cells impede differentiation of adipocytes, leading to insulin resistance.[44]

SASP factors IL-6 and TNFα enhance T-cell apoptosis, thereby impairing the capacity of the adaptive immune system.[45]

SASP factors from senescent cells reduce nicotinamide adenine dinucleotide (NAD+) in non-senescent cells,[46] thereby reducing the capacity for DNA repair and sirtuin activity in non-senescent cells.[47] SASP induction of the NAD+ degrading enzyme CD38 on non-senescent cells (macrophages) may be responsible for most of this effect.[37][48][49] By contrast, NAD+ contributes to the secondary (pro-inflammatory) manifestation of SASP.[7]

SASP induces an unfolded protein response in the endoplasmic reticulum because of an accumulation of unfolded proteins, resulting in proteotoxic impairment of cell function.[50]

SASP cytokines can result in an inflamed stem cell niche, leading to stem cell exhaustion and impaired stem cell function.[37]

SASP can either promote or inhibit cancer, depending on the SASP composition,[39] notably including p53 status.[51] Despite the fact that cellular senescence likely evolved as a means of protecting against cancer early in life, SASP promotes the development of late-life cancers.[18][43] Cancer invasiveness is promoted primarily though the actions of the SASP factors metalloproteinase, chemokine, interleukin 6 (IL-6), and interleukin 8 (IL-8).[52][1] In fact, SASP from senescent cells is associated with many aging-associated diseases, including not only cancer, but atherosclerosis and osteoarthritis.[2] For this reason, senolytic therapy has been proposed as a generalized treatment for these and many other diseases.[2] The flavonoid apigenin has been shown to strongly inhibit SASP production.[53]

Benefits

[edit]

SASP can aid in signaling to immune cells for senescent cell clearance,[54][55][56][57] with specific SASP factors secreted by senescent cells attracting and activating different components of both the innate and adaptive immune system.[55] The SASP cytokine CCL2 (MCP1) recruits macrophages to remove cancer cells.[58] Although transient expression of SASP can recruit immune system cells to eliminate cancer cells as well as senescent cells, chronic SASP promotes cancer.[59] Senescent hematopoietic stem cells produces a SASP that induces an M1 polarization of macrophages which kills the senescent cells in a p53-dependent process.[60]

Autophagy is upregulated to promote survival.[50]

SASP factors can maintain senescent cells in their senescent state of growth arrest, thereby preventing cancerous transformation.[61] Additionally, SASP secreted by cells that have become senescent because of stresses can induce senescence in adjoining cells subject to the same stresses. thereby reducing cancer risk.[26]

SASP can play a beneficial role by promoting wound healing.[62][63] SASP may play a role in tissue regeneration by signaling for senescent cell clearance by immune cells, allowing progenitor cells to repopulate tissue.[64] In development, SASP also may be used to signal for senescent cell clearance to aid tissue remodeling.[65] The ability of SASP to clear senescent cells and regenerate damaged tissue declines with age.[66] In contrast to the persistent character of SASP in the chronic inflammation of multiple age-related diseases, beneficial SASP in wound healing is transitory.[62][63] Temporary SASP in the liver or kidney can reduce fibrosis, but chronic SASP could lead to organ dysfunction.[67][68]

Modification

[edit]

Senescent cells have permanently active mTORC1 irrespective of nutrients or growth factors, resulting in the continuous secretion of SASP.[69] By inhibiting mTORC1, rapamycin reduces SASP production by senescent cells.[69]

SASP has been reduced through inhibition of p38 mitogen-activated protein kinases and janus kinase.[70]

The protein hnRNP A1 (heterogeneous nuclear ribonucleoprotein A1) antagonizes cellular senescence and induction of the SASP by stabilizing Oct-4 and sirtuin 1 mRNAs.[71][72]

SASP Index

[edit]

A SASP index composed of 22 SASP factors has been used to evaluate treatment outcomes of late life depression.[73] Higher SASP index scores corresponded to increased incidence of treatment failure, whereas no individual SASP factors were associated with treatment failure.[73]

Inflammaging

[edit]
Main article: Inflammaging

Chronic inflammation associated with aging has been termed inflammaging, although SASP may be only one of the possible causes of this condition.[74] Chronic systemic inflammation is associated with aging-associated diseases.[51] Senolytic agents have been recommended to counteract some of these effects.[11] Chronic inflammation due to SASP can suppress immune system function,[3] which is one reason elderly persons are more vulnerable to COVID-19.[75]

See also

[edit]

References

[edit]
  1. ^ a b c Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. (December 2008). "Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor". PLOS Biology. 6 (12): 2853–2868. doi:10.1371/journal.pbio.0060301. PMC 2592359. PMID 19053174.
  2. ^ a b c Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, et al. (October 2017). "Senescent cells: an emerging target for diseases of ageing". Nature Reviews. Drug Discovery. 16 (10): 718–735. doi:10.1038/nrd.2017.116. PMC 5942225. PMID 28729727.
  3. ^ a b Prata LG, Ovsyannikova IG, Tchkonia T, Kirkland JL (December 2018). "Senescent cell clearance by the immune system: Emerging therapeutic opportunities". Seminars in Immunology. 40: 101275. doi:10.1016/j.smim.2019.04.003. PMC 7061456. PMID 31088710.
  4. ^ a b c Birch J, Gil J (December 2020). "Senescence and the SASP: many therapeutic avenues". Genes & Development. 34 (23–24): 1565–1576. doi:10.1101/gad.343129.120. PMC 7706700. PMID 33262144.
  5. ^ Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. (July 2020). "Senolytic CAR T cells reverse senescence-associated pathologies". Nature. 583 (7814): 127–132. Bibcode:2020Natur.583..127A. doi:10.1038/s41586-020-2403-9. PMC 7583560. PMID 32555459.
  6. ^ Ito Y, Hoare M, Narita M (November 2017). "Spatial and Temporal Control of Senescence". Trends in Cell Biology. 27 (11): 820–832. doi:10.1016/j.tcb.2017.07.004. PMID 28822679.
  7. ^ a b Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, et al. (March 2019). "NAD+ metabolism governs the proinflammatory senescence-associated secretome". Nature Cell Biology. 21 (3): 397–407. doi:10.1038/s41556-019-0287-4. PMC 6448588. PMID 30778219.
  8. ^ a b Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, et al. (January 2020). "A proteomic atlas of senescence-associated secretomes for aging biomarker development". PLOS Biology. 18 (1): e3000599. doi:10.1371/journal.pbio.3000599. PMC 6964821. PMID 31945054.
  9. ^ a b Maciel-Barón LA, Morales-Rosales SL, Aquino-Cruz AA, Triana-Martínez F, Galván-Arzate S, Luna-López A, et al. (February 2016). "Senescence associated secretory phenotype profile from primary lung mice fibroblasts depends on the senescence induction stimuli". Age. 38 (1): 26. doi:10.1007/s11357-016-9886-1. PMC 5005892. PMID 26867806.
  10. ^ Partridge L, Fuentealba M, Kennedy BK (August 2020). "The quest to slow ageing through drug discovery". Nature Reviews. Drug Discovery. 19 (8): 513–532. doi:10.1038/s41573-020-0067-7. PMID 32467649. S2CID 218912510.
  11. ^ a b Chambers ES, Akbar AN (May 2020). "Can blocking inflammation enhance immunity during aging?". The Journal of Allergy and Clinical Immunology. 145 (5): 1323–1331. doi:10.1016/j.jaci.2020.03.016. PMID 32386656.
  12. ^ a b Herdy JR, Mertens J, Gage FH (June 2024). "Neuronal senescence may drive brain aging". Science. 384 (6703): 1404–1406. Bibcode:2024Sci...384.1404H. doi:10.1126/science.adi3450. PMID 38935713.
  13. ^ Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E (July 2019). "From discoveries in ageing research to therapeutics for healthy ageing". Nature. 571 (7764): 183–192. Bibcode:2019Natur.571..183C. doi:10.1038/s41586-019-1365-2. PMC 7205183. PMID 31292558.
  14. ^ Khosla S, Farr JN, Tchkonia T, Kirkland JL (May 2020). "The role of cellular senescence in ageing and endocrine disease". Nature Reviews. Endocrinology. 16 (5): 263–275. doi:10.1038/s41574-020-0335-y. PMC 7227781. PMID 32161396.
  15. ^ Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D (December 2019). "Targeting senescent cells in translational medicine". EMBO Molecular Medicine. 11 (12): e10234. doi:10.15252/emmm.201810234. PMC 6895604. PMID 31746100.
  16. ^ Kirkland JL, Tchkonia T (November 2020). "Senolytic drugs: from discovery to translation". Journal of Internal Medicine. 288 (5): 518–536. doi:10.1111/joim.13141. PMC 7405395. PMID 32686219.
  17. ^ a b Booth LN, Brunet A (June 2016). "The Aging Epigenome". Molecular Cell. 62 (5): 728–744. doi:10.1016/j.molcel.2016.05.013. PMC 4917370. PMID 27259204.
  18. ^ a b Ghosh K, Capell BC (November 2016). "The Senescence-Associated Secretory Phenotype: Critical Effector in Skin Cancer and Aging". The Journal of Investigative Dermatology. 136 (11): 2133–2139. doi:10.1016/j.jid.2016.06.621. PMC 5526201. PMID 27543988.
  19. ^ Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. (June 2008). "Chemokine signaling via the CXCR2 receptor reinforces senescence". Cell. 133 (6): 1006–1018. doi:10.1016/j.cell.2008.03.038. PMID 18555777. S2CID 6708172.
  20. ^ Yarbro JR, Emmons RS, Pence BD (June 2020). "Macrophage Immunometabolism and Inflammaging: Roles of Mitochondrial Dysfunction, Cellular Senescence, CD38, and NAD". Immunometabolism. 2 (3): e200026. doi:10.20900/immunometab20200026. PMC 7409778. PMID 32774895.
  21. ^ a b Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aron L, et al. (September 2015). "The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4". Science. 349 (6255): aaa5612. doi:10.1126/science.aaa5612. PMC 4942138. PMID 26404840.
  22. ^ a b Yessenkyzy A, Saliev T, Zhanaliyeva M, Masoud AR, Umbayev B, Sergazy S, et al. (May 2020). "Polyphenols as Caloric-Restriction Mimetics and Autophagy Inducers in Aging Research". Nutrients. 12 (5): 1344. doi:10.3390/nu12051344. PMC 7285205. PMID 32397145.
  23. ^ Rossiello F, Jurk D, Passos JF, d'Adda di Fagagna F (February 2022). "Telomere dysfunction in ageing and age-related diseases". Nature Cell Biology. 24 (2): 135–147. doi:10.1038/s41556-022-00842-x. PMC 8985209. PMID 35165420.
  24. ^ Anerillas C, Abdelmohsen K, Gorospe M (April 2020). "Regulation of senescence traits by MAPKs". GeroScience. 42 (2): 397–408. doi:10.1007/s11357-020-00183-3. PMC 7205942. PMID 32300964.
  25. ^ Nelson G, Wordsworth J, von Zglinicki T (2013). "A senescent cell bystander effect: senescence-induced senescence". Aging Cell. 11 (2): 345–349. doi:10.1111/j.1474-9726.2012.00795.x. PMC 3488292. PMID 22321662.
  26. ^ a b Herranz N, Gil J (April 2018). "Mechanisms and functions of cellular senescence". The Journal of Clinical Investigation. 128 (4): 1238–1246. doi:10.1172/JCI95148. PMC 5873888. PMID 29608137.
  27. ^ a b Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. (August 2015). "MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation". Nature Cell Biology. 17 (8): 1049–1061. doi:10.1038/ncb3195. PMC 4691706. PMID 26147250.
  28. ^ Wang R, Yu Z, Sunchu B, Shoaf J, Dang I, Zhao S, et al. (June 2017). "Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism". Aging Cell. 16 (3): 564–574. doi:10.1111/acel.12587. PMC 5418203. PMID 28371119.
  29. ^ Sharma R, Padwad Y (September 2019). "In search of nutritional anti-aging targets: TOR inhibitors, SASP modulators, and BCL-2 family suppressors". Nutrition. 65: 33–38. doi:10.1016/j.nut.2019.01.020. PMID 31029919. S2CID 86541289.
  30. ^ Wang R, Sunchu B, Perez VI (August 2017). "Rapamycin and the inhibition of the secretory phenotype". Experimental Gerontology. 94: 89–92. doi:10.1016/j.exger.2017.01.026. PMID 28167236. S2CID 4960885.
  31. ^ Weichhart T (2018). "mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review". Gerontology. 64 (2): 127–134. doi:10.1159/000484629. PMC 6089343. PMID 29190625.
  32. ^ a b Papadopoli D, Boulay K, Kazak L, Pollak M, Mallette FA, Topisirovic I, et al. (2019). "mTOR as a central regulator of lifespan and aging". F1000Research. 8: 998. doi:10.12688/f1000research.17196.1. PMC 6611156. PMID 31316753.
  33. ^ Carosi JM, Fourrier C, Bensalem J, Sargeant TJ (April 2022). "The mTOR-lysosome axis at the centre of ageing". FEBS Open Bio. 12 (4): 739–757. doi:10.1002/2211-5463.13347. PMC 8972043. PMID 34878722.
  34. ^ Paredes S, Angulo-Ibanez M, Tasselli L, Carlson SM, Zheng W, Li TM, et al. (July 2018). "The epigenetic regulator SIRT7 guards against mammalian cellular senescence induced by ribosomal DNA instability". The Journal of Biological Chemistry. 293 (28): 11242–11250. doi:10.1074/jbc.AC118.003325. PMC 6052228. PMID 29728458.
  35. ^ a b Huda N, Liu G, Hong H, Yan S, Khambu B, Yin XM (September 2019). "Hepatic senescence, the good and the bad". World Journal of Gastroenterology. 25 (34): 5069–5081. doi:10.3748/wjg.v25.i34.5069. PMC 6747293. PMID 31558857.
  36. ^ Yang H, Wang H, Ren J, Chen Q, Chen ZJ (June 2017). "cGAS is essential for cellular senescence". Proceedings of the National Academy of Sciences of the United States of America. 114 (23): E4612–E4620. Bibcode:2017PNAS..114E4612Y. doi:10.1073/pnas.1705499114. PMC 5468617. PMID 28533362.
  37. ^ a b c Baechle JJ, Chen N, Makhijani P, Winer S, Furman D, Winer DA (August 2023). "Chronic inflammation and the hallmarks of aging". Molecular Metabolism. 74: 101755. doi:10.1016/j.molmet.2023.101755. PMC 10359950. PMID 37329949.
  38. ^ López-Polo V, Maus M, Zacharioudakis E, Lafarga M, Attolini CS, Marques FD, et al. (2024-08-27). "Release of mitochondrial dsRNA into the cytosol is a key driver of the inflammatory phenotype of senescent cells". Nature Communications. 15 (1): 7378. Bibcode:2024NatCo..15.7378L. doi:10.1038/s41467-024-51363-0. ISSN 2041-1723. PMC 11349883. PMID 39191740.
  39. ^ a b Liu XL, Ding J, Meng LH (October 2018). "Oncogene-induced senescence: a double edged sword in cancer". Acta Pharmacologica Sinica. 39 (10): 1553–1558. doi:10.1038/aps.2017.198. PMC 6289471. PMID 29620049.
  40. ^ Houssaini A, Breau M, Kebe K, Abid S, Marcos E, Lipskaia L, et al. (February 2018). "mTOR pathway activation drives lung cell senescence and emphysema". JCI Insight. 3 (3): e93203. doi:10.1172/jci.insight.93203. PMC 5821218. PMID 29415880.
  41. ^ Acosta JC, Banito A, Wuestefeld T (2013). "A complex secretory program orchestrated by the inflammasome controls paracrine senescence". Nature Cell Biology. 15 (8): 970–990. doi:10.1038/ncb2784. PMC 3732483. PMID 23770676.
  42. ^ Palmer AK, Gustafson B, Kirkland JL, Smith U (October 2019). "Cellular senescence: at the nexus between ageing and diabetes". Diabetologia. 62 (10): 1835–1841. doi:10.1007/s00125-019-4934-x. PMC 6731336. PMID 31451866.
  43. ^ a b van Deursen JM (May 2019). "Senolytic therapies for healthy longevity". Science. 364 (6441): 636–637. Bibcode:2019Sci...364..636V. doi:10.1126/science.aaw1299. PMC 6816502. PMID 31097655.
  44. ^ Palmer AK, Kirkland JL (December 2016). "Aging and adipose tissue: potential interventions for diabetes and regenerative medicine". Experimental Gerontology. 86: 97–105. doi:10.1016/j.exger.2016.02.013. PMC 5001933. PMID 26924669.
  45. ^ Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E (September 2021). "SARS-CoV-2, COVID-19 and the Ageing Immune System". Nature Aging. 1 (9): 769–782. doi:10.1038/s43587-021-00114-7. PMC 8570568. PMID 34746804.
  46. ^ Chini C, Hogan KA, Warner GM, Tarragó MG, Peclat TR, Tchkonia T, et al. (May 2019). "The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD+ decline". Biochemical and Biophysical Research Communications. 513 (2): 486–493. doi:10.1016/j.bbrc.2019.03.199. PMC 6486859. PMID 30975470.
  47. ^ Verdin E (December 2015). "NAD⁺ in aging, metabolism, and neurodegeneration". Science. 350 (6265): 1208–1213. Bibcode:2015Sci...350.1208V. doi:10.1126/science.aac4854. PMID 26785480. S2CID 27313960.
  48. ^ Sabbatinelli J, Prattichizzo F, Olivieri F, Procopio AD, Rippo MR, Giuliani A (2019). "Where Metabolism Meets Senescence: Focus on Endothelial Cells". Frontiers in Physiology. 10: 1523. doi:10.3389/fphys.2019.01523. PMC 6930181. PMID 31920721.
  49. ^ Covarrubias AJ, Perrone R, Grozio A, Verdin E (February 2021). "NAD+ metabolism and its roles in cellular processes during ageing". Nature Reviews. Molecular Cell Biology. 22 (2): 119–141. doi:10.1038/s41580-020-00313-x. PMC 7963035. PMID 33353981.
  50. ^ a b Soto-Gamez A, Quax WJ, Demaria M (July 2019). "Regulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions". Journal of Molecular Biology. 431 (15): 2629–2643. doi:10.1016/j.jmb.2019.05.036. PMID 31153901.
  51. ^ a b Prašnikar E, Borišek J, Perdih A (March 2021). "Senescent cells as promising targets to tackle age-related diseases". Ageing Research Reviews. 66: 101251. doi:10.1016/j.arr.2020.101251. PMID 33385543.
  52. ^ Kim YH, Park TJ (January 2019). "Cellular senescence in cancer". BMB Reports. 52 (1): 42–46. doi:10.5483/BMBRep.2019.52.1.295. PMC 6386235. PMID 30526772.
  53. ^ Lim H, Heo MY, Kim HP (May 2019). "Flavonoids: Broad Spectrum Agents on Chronic Inflammation". Biomolecules & Therapeutics. 27 (3): 241–253. doi:10.4062/biomolther.2019.034. PMC 6513185. PMID 31006180.
  54. ^ Katlinskaya YV, Carbone CJ, Yu Q, Fuchs SY (2015). "Type 1 interferons contribute to the clearance of senescent cell". Cancer Biology & Therapy. 16 (8): 1214–1219. doi:10.1080/15384047.2015.1056419. PMC 4622626. PMID 26046815.
  55. ^ a b Sagiv A, Krizhanovsky V (December 2013). "Immunosurveillance of senescent cells: the bright side of the senescence program". Biogerontology. 14 (6): 617–628. doi:10.1007/s10522-013-9473-0. PMID 24114507. S2CID 2775067.
  56. ^ Thiers B (January 2008). "Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas". Yearbook of Dermatology and Dermatologic Surgery. 2008: 312–313. doi:10.1016/s0093-3619(08)70921-3. ISSN 0093-3619.
  57. ^ Rao SG, Jackson JG (November 2016). "SASP: Tumor Suppressor or Promoter? Yes!". Trends in Cancer. 2 (11): 676–687. doi:10.1016/j.trecan.2016.10.001. PMID 28741506.
  58. ^ Alexander E, Hildebrand DG, Kriebs A, Obermayer K, Manz M, Rothfuss O, et al. (August 2013). "IκBζ is a regulator of the senescence-associated secretory phenotype in DNA damage- and oncogene-induced senescence". Journal of Cell Science. 126 (Pt 16): 3738–3745. doi:10.1242/jcs.128835. PMID 23781024.
  59. ^ Yang J, Liu M, Hong D, Zeng M, Zhang X (2021). "The Paradoxical Role of Cellular Senescence in Cancer". Frontiers in Cell and Developmental Biology. 9: 722205. doi:10.3389/fcell.2021.722205. PMC 8388842. PMID 34458273.
  60. ^ Lujambio A (July 2016). "To clear, or not to clear (senescent cells)? That is the question". BioEssays. 38 Suppl 1 (Suppl 1): S56–S64. doi:10.1002/bies.201670910. PMID 27417123. S2CID 3785916.
  61. ^ Freund A, Orjalo AV, Desprez PY, Campisi J (May 2010). "Inflammatory networks during cellular senescence: causes and consequences". Trends in Molecular Medicine. 16 (5): 238–246. doi:10.1016/j.molmed.2010.03.003. PMC 2879478. PMID 20444648.
  62. ^ a b Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. (December 2014). "An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA". Developmental Cell. 31 (6): 722–733. doi:10.1016/j.devcel.2014.11.012. PMC 4349629. PMID 25499914.
  63. ^ a b Basisty N, Kale A, Patel S, Campisi J, Schilling B (April 2020). "The power of proteomics to monitor senescence-associated secretory phenotypes and beyond: toward clinical applications". Expert Review of Proteomics. 17 (4): 297–308. doi:10.1080/14789450.2020.1766976. PMC 7416420. PMID 32425074.
  64. ^ Muñoz-Espín D, Serrano M (July 2014). "Cellular senescence: from physiology to pathology". Nature Reviews. Molecular Cell Biology. 15 (7): 482–496. doi:10.1038/nrm3823. PMID 24954210. S2CID 20062510.
  65. ^ Muñoz-Espín D, Cañamero M, Maraver A, Gómez-López G, Contreras J, Murillo-Cuesta S, et al. (November 2013). "Programmed cell senescence during mammalian embryonic development". Cell. 155 (5): 1104–1118. doi:10.1016/j.cell.2013.10.019. hdl:20.500.11940/3668. PMID 24238962.
  66. ^ Zhu Y, Liu X, Ding X, Wang F, Geng X (February 2019). "Telomere and its role in the aging pathways: telomere shortening, cell senescence and mitochondria dysfunction". Biogerontology. 20 (1): 1–16. doi:10.1007/s10522-018-9769-1. PMID 30229407.
  67. ^ Zhang M, Serna-Salas S, Damba T, Borghesan M, Demaria M, Moshage H (October 2021). "Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives". Mechanisms of Ageing and Development. 199: 111572. doi:10.1016/j.mad.2021.111572. PMID 34536446. S2CID 237524296.
  68. ^ Valentijn FA, Falke LL, Nguyen TQ, Goldschmeding R (March 2018). "Cellular senescence in the aging and diseased kidney". Journal of Cell Communication and Signaling. 12 (1): 69–82. doi:10.1007/s12079-017-0434-2. PMC 5842195. PMID 29260442.
  69. ^ a b Liu GY, Sabatini DM (April 2020). "mTOR at the nexus of nutrition, growth, ageing and disease". Nature Reviews. Molecular Cell Biology. 21 (4): 183–203. doi:10.1038/s41580-019-0199-y. PMC 7102936. PMID 31937935.
  70. ^ Ji S, Xiong M, Chen H, Liu Y, Zhou L, Hong Y, et al. (March 2023). "Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases". Signal Transduction and Targeted Therapy. 8 (1): 116. doi:10.1038/s41392-023-01343-5. PMC 10015098. PMID 36918530.
  71. ^ Han YM, Ramprasath T, Zou MH (April 2020). "β-hydroxybutyrate and its metabolic effects on age-associated pathology". Experimental & Molecular Medicine. 52 (4): 548–555. doi:10.1038/s12276-020-0415-z. PMC 7210293. PMID 32269287.
  72. ^ Stubbs BJ, Koutnik AP, Volek JS, Newman JC (June 2021). "From bedside to battlefield: intersection of ketone body mechanisms in geroscience with military resilience". GeroScience. 43 (3): 1071–1081. doi:10.1007/s11357-020-00277-y. PMC 8190215. PMID 33006708.
  73. ^ a b Diniz BS, Mulsant BH, Reynolds CF, Blumberger DM, Karp JF, Butters MA, et al. (June 2022). "Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome". JAMA Network Open. 5 (6): e2219678. doi:10.1001/jamanetworkopen.2022.19678. PMC 9247739. PMID 35771573.
  74. ^ Franceschi C, Campisi J (June 2014). "Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 69 Suppl 1 (Supp 1): S4–S9. doi:10.1093/gerona/glu057. PMID 24833586.
  75. ^ Akbar AN, Gilroy DW (July 2020). "Aging immunity may exacerbate COVID-19". Science. 369 (6501): 256–257. Bibcode:2020Sci...369..256A. doi:10.1126/science.abb0762. PMID 32675364.

For further reading

[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Senescence-associated_secretory_phenotype&oldid=1248654574"